Serum profiles of monocyte chemoattractant protein-1 as a biomarker for patients recovering from myocardial infarction

Clinical Research in Cardiology

Volumn 99, Issue 5, 2010, Pages 315-322

  Korybalska, Katarzyna ^a   Pyda, Małgorzata ^a   Grajek, Stefan ^a   Łanocha, Magdalena ^a   Brȩborowicz, Andrzej ^a   Witowski, Janusz ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Acute coronary syndrome; Left ventricular function; Monocyte chemoattractant protein 1; Restenosis

Indexed keywords

ATORVASTATIN; MONOCYTE CHEMOTACTIC PROTEIN 1; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; FEMALE; HEART MUSCLE REPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; RESTENOSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

AGED; BIOLOGICAL MARKERS; CHEMOKINE CCL2; DIAGNOSIS, COMPUTER-ASSISTED; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECOVERY OF FUNCTION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 77954658890     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-010-0122-1     Document Type: Article

References (50)

1. Bonaca MP, Morrow DA (2008) Defining a role for novel biomarkers in acute coronary syndromes. Clin Chem 54:1424-1431
2. O'Donoghue M, Morrow DA (2008) The future of biomarkers in the management of patients with acute coronary syndromes. Curr Opin Cardiol 23:309-314
3. Charo IF, Taubman MB (2004) Chemokines in the pathogenesis of vascular disease. Circ Res 95:858-866
4. Braunersreuther V, Mach F, Steffens S (2007) The specific role of chemokines in atherosclerosis. Thromb Haemost 97:714-721
5. Aukrust P, Halvorsen B, Yndestad A, Ueland T, Oie E, Otterdal K et al (2008) Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol 28:1909-1919
6. Frangogiannis NG, Dewald O, Xia Y, Ren G, Haudek S, Leucker T et al (2007) Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy. Circulation 115:584-592
7. Deo R, Khera A, McGuire DK, Murphy SA, Meo Neto JP, Morrow DA et al (2004) Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 44:1812-1818
8. de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM et al (2003) Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 107:690-695
9. Kervinen H, Manttari M, Kaartinen M, Makynen H, Palosuo T, Pulkki K et al (2004) Prognostic usefulness of plasma monocyte/ macrophage and T-lymphocyte activation markers in patients with acute coronary syndromes. Am J Cardiol 94:993-996
10. Waehre T, Damas JK, Gullestad L, Holm AM, Pedersen TR, Arnesen KE et al (2003) Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol 41:1460-1467
11. Xu ZM, Zhao SP, Li QZ, Nie S, Zhou HN (2003) Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clin Chim Acta 338:17-24
12. Lewandowski M, Kornacewicz-Jach Z, Millo B, Zielonka J, Czechowska M, Kaliszczak R et al (2008) The influence of low dose atorvastatin on inflammatory marker levels in patients with acute coronary syndrome and its potential clinical value. Cardiol J 15:357-364
13. de Lemos JA, Morrow DA, Blazing MA, Jarolim P, Wiviott SD, Sabatine MS et al (2007) Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol 50:2117-2124
14. Morimoto H, Takahashi M, Izawa A, Ise H, Hongo M, Kolattukudy PE et al (2006) Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction. Circ Res 99:891-899
15. Morimoto H, Hirose M, Takahashi M, Kawaguchi M, Ise H, Kolattukudy PE et al (2008) MCP-1 induces cardioprotection against ischaemia/reperfusion injury: role of reactive oxygen species. Cardiovasc Res 78:554-562
16. Frangogiannis NG, Shimoni S, Chang SM, Ren G, Shan K, Aggeli C et al (2002) Evidence for an active inflammatory process in the hibernating human myocardium. Am J Pathol 160:1425-1433 (Pubitemid 34411645)
17. Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T et al (2005) CCL2/Monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 96:881-889
18. Dobaczewski M, Frangogiannis NG (2009) Chemokines and cardiac fibrosis. Front Biosci (Schol Ed) 1:391-405
19. Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM et al (2002) Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation 106:2351-2357
20. Debrunner M, Schuiki E, Minder E, Straumann E, Naegeli B, Mury R et al (2008) Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. Clin Res Cardiol 97:298-305
21. El Menyar AA (2008) Cytokines and coronary artery disease: the state of the art. Crit Pathw Cardiol 7:139-151
22. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-1695
23. Frangogiannis NG (2007) The prognostic value of monocyte chemoattractant protein-1/CCL2 in acute coronary syndromes. J Am Coll Cardiol 50:2125-2127
24. Murakami Y, Kurosaki K, Matsui K, Shimada K, Ikeda U (2003) Serum MCP-1 and VEGF levels are not affected by inhibition of the renin-angiotensin system in patients with acute myocardial infarction. Cardiovasc Drugs Ther 17:249-255
25. Hoogeveen RC, Morrison A, Boerwinkle E, Miles JS, Rhodes CE, Sharrett AR et al (2005) Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: atherosclerosis risk in communities study. Atherosclerosis 183:301-307
26. Nishiyama K, Ogawa H, Yasue H, Soejima H, Misumi K, Takazoe K et al (1998) Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes. Jpn Circ J 62:710-712
27. McDermott DH, Yang Q, Kathiresan S, Cupples LA, Massaro JM, Keaney JF Jr et al (2005) CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the framingham heart study. Circulation 112:1113-1120
28. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA Jr et al (1999) MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398:718-723
29. Lukacs NW, Strieter RM, Elner V, Evanoff HL, Burdick MD, Kunkel SL (1995) Production of chemokines, interleukin-8 and monocyte chemoattractant protein-1, during monocyte: endothelial cell interactions. Blood 86:2767-2773
30. Hohensinner PJ, Kaun C, Rychli K, Ben Tal CE, Kastl SP, Demyanets S et al (2006) Monocyte chemoattractant protein (MCP-1) is expressed in human cardiac cells and is differentially regulated by inflammatory mediators and hypoxia. FEBS Lett 580:3532-3538
31. Flamant L, Toffoli S, Raes M, Michiels C (2009) Hypoxia regulates inflammatory gene expression in endothelial cells. Exp Cell Res 315:733-747
32. Bosco MC, Puppo M, Pastorino S, Mi Z, Melillo G, Massazza S et al (2004) Hypoxia selectively inhibits monocyte chemoattractant protein-1 production by macrophages. J Immunol 172:1681-1690
33. Negus RP, Turner L, Burke F, Balkwill FR (1998) Hypoxia down-regulates MCP-1 expression: implications for macrophage distribution in tumors. J Leukoc Biol 63:758-765
34. Schirmer SH, Fledderus JO, van der Laan AM, van der Pouw-Kraan TC, Moerland PD, Volger OL et al (2009) Suppression of inflammatory signaling in monocytes from patients with coronary artery disease. J Mol Cell Cardiol 46:177-185
35. Gabrielsen A, Lawler PR, Yongzhong W, Steinbruchel D, Blagoja D, Paulsson-Berne G et al (2007) Gene expression signals involved in ischemic injury, extracellular matrix composition and fibrosis defined by global mRNA profiling of the human left ventricular myocardium. J Mol Cell Cardiol 42:870-883
36. Kuschert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, Hoogewerf AJ et al (1999) Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 38:12959-12968
37. Pyda M, Korybalska K, Ksiazek K, Grajek S, Lanocha M, Lesiak M et al (2006) Effect of heparin on blood vascular endothelial growth factor levels in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 98:902-905
38. Niu J, Kolattukudy PE (2009) Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin Sci (Lond) 117:95-109
39. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL et al (2007) The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 204:3037-3047
40. Tsujioka H, Imanishi T, Ikejima H, Kuroi A, Takarada S, Tanimoto T et al (2009) Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J Am Coll Cardiol 54:130-138
41. Sako H, Miura S, Iwata A, Nishikawa H, Kawamura A, Matsuo K et al (2008) Changes in CCR2 chemokine receptor expression and plasma MCP-1 concentration after the implantation of bare metal stents versus sirolimus-eluting stents in patients with stable angina. Intern Med 47:7-13
42. Inami N, Nomura S, Shimazu T, Manabe K, Kimura Y, Iwasaka T (2007) Adiponectin incompletely prevent MCP-1-dependent restenosis after percutaneous coronary intervention in patients with coronary artery disease. J Thromb Thrombolysis 24:267-273
43. Hognestad A, Endresen K, Wergeland R, Mellembakken JR, Mollnes TE, Omland T et al (2005) Inflammatory response and re-stenosis after percutaneous coronary intervention in heart transplant recipients and patients with native atherosclerosis. J Heart Lung Transplant 24:1026-1032
44. Cipollone F, Marini M, Fazia M, Pini B, Iezzi A, Reale M et al (2001) Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 21:327-334 (Pubitemid 32199112)
45. Usui M, Egashira K, Ohtani K, Kataoka C, Ishibashi M, Hiasa K et al (2002) Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys. FASEB J 16:1838-1840
46. Toutouzas K, Colombo A, Stefanadis C (2004) Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J 25:1679-1687
47. Cavusoglu E, Eng C, Chopra V, Clark LT, Pinsky DJ, Marmur JD (2007) Low plasma RANTES levels are an independent predictor of cardiac mortality in patients referred for coronary angiography. Arterioscler Thromb Vasc Biol 27:929-935
48. Tarzami ST, Calderon TM, Deguzman A, Lopez L, Kitsis RN, Berman JW (2005) MCP-1/CCL2 protects cardiac myocytes from hypoxia-induced apoptosis by a G (alphai)-independent pathway. Biochem Biophys Res Commun 335:1008-1016
49. Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti N et al (2000) Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 80:1095-1100
50. Morikawa S, Takabe W, Mataki C, Kanke T, Itoh T, Wada Y et al (2002) The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 9:178-183